Share

January 2023; 10 (1) Research ArticleOpen Access

Long-term Efficacy of Satralizumab in AQP4-IgG–Seropositive Neuromyelitis Optica Spectrum Disorder From SAkuraSky and SAkuraStar

Ingo Kleiter, Anthony Traboulsee, Jacqueline Palace, Takashi Yamamura, Kazuo Fujihara, Albert Saiz, Adil Javed, David Mayes, H-Christian von Büdingen, Gaelle Klingelschmitt, Daniela Stokmaier, Jeffrey L. Bennett
First published December 8, 2022, DOI: https://doi.org/10.1212/NXI.0000000000200071
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
1217

Share

Article Figures & Data

Figures

  • Figure 1
    Figure 1 Flowchart of AQP4-IgG Seropositive Patients in the SAkura Studies

    *One patient joined directly into the OLE and remained in the trial at the cutoff for the current analysis (February 22, 2021). Where patients withdrew consent, this applied to all data collection from that point onward, not prior. AQP4-IgG = aquaporin-4-immunoglobulin G; CCOD = clinical cutoff date; DB = double-blind; OLE = open-label extension; R = randomization.

  • Figure 2
    Figure 2 Kaplan-Meier Analysis of Time to First iPDR in the Total Satralizumab Treatment Periods of (A) SAkuraSky and (B) SAkuraStar

    PBO = placebo; SAT = satralizumab.

  • Figure 3
    Figure 3 Swim Plot of iPDR Events in All Patients Who Received Satralizumab in SAkuraSky and SAkuraStar

    iPDR = investigator-reported protocol-defined relapse.

  • Figure 4
    Figure 4 Kaplan-Meier Analysis of Time to First Severe iPDR in the Total Satralizumab Treatment Periods of (A) SAkuraSky and (B) SAkuraStar

    iPDR = investigator-reported protocol-defined relapse; PBO = placebo; SAT = satralizumab.

  • Figure 5
    Figure 5 Kaplan-Meier Analysis of Time to First Sustained EDSS Worsening in the Total Satralizumab Treatment Periods of (A) SAkuraSky and (B) SAkuraStar

    EDSS = Expanded Disability Status Scale; PBO = placebo; SAT = satralizumab.

Tables

  • Table 1
  • Table 2
  • Table

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Alert Me